In short
ProTrans, a groundbreaking cell therapy derived from Wharton's Jelly Mesenchymal Stromal Cells (WJMSCs), is being studied in clinical trials for its potential to preserve insulin production in adults with Type 1 Diabetes. These trials aim to evaluate the safety, efficacy, and impact of ProTrans on patients' insulin requirements and overall diabetes management.
At a glance
- Treatment
- ProTrans (Wharton's Jelly Mesenchymal Stromal Cells)
- Condition
- Type 1 Diabetes in adults
- Administration
- Single intravenous infusion
- Dosage
- 25 million to 200 million cells per patient
- Primary Outcomes
- Safety, changes in C-peptide levels
- Secondary Outcomes
- Insulin requirements, HbA1c, glucose variability
- Study Duration
- One year follow-up
- Key Assessment Points
- Day 187 and Day 372 after infusion
What is ProTrans?
ProTrans is an innovative medical treatment being developed for Type 1 Diabetes. It is a cell-based therapy that uses special cells called Wharton's Jelly-derived Mesenchymal Stromal Cells (WJMSCs). These cells are obtained from the umbilical cord tissue, which is rich in healing and regenerative properties.
ProTrans is also known by other names, including:
- Allogeneic transplantation with WJMSCs
- Wharton's Jelly Derived Mesenchymal Stromal Cell treatment
How ProTrans Works
ProTrans is designed to help preserve the body's ability to produce insulin in patients with Type 1 Diabetes. In this condition, the body's immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. ProTrans aims to:
- Protect remaining insulin-producing cells
- Potentially regenerate damaged cells
- Modulate the immune system to prevent further damage
The treatment involves a single infusion of these special cells directly into the patient's bloodstream. The number of cells used can vary, with researchers testing different doses to find the most effective treatment.
Clinical Trials of ProTrans
ProTrans is currently being studied in clinical trials to determine its safety and effectiveness. Two main studies are underway:
- Repeated Treatment Study: This is a Phase I/II study involving 18 adult male patients aged 18-41 who have been diagnosed with Type 1 Diabetes for less than 3.5 years. The study aims to test different doses of ProTrans and evaluate its safety and effects on insulin production.
- Double-Blinded Study: This is a combined Phase I and II study involving 24 patients aged 18-40, both male and female. It compares ProTrans treatment to a placebo to assess its safety and effectiveness in preserving insulin production.
Potential Benefits of ProTrans
The clinical trials are investigating several potential benefits of ProTrans, including:
- Preserved insulin production: Measured by C-peptide levels, which indicate how much insulin the body is producing
- Reduced insulin requirements: Some patients might need less external insulin or potentially become insulin-independent
- Improved blood sugar control: Measured by HbA1c levels and glucose variability
- Enhanced quality of life: Assessed through diabetes treatment satisfaction questionnaires
Safety Considerations
The primary focus of these clinical trials is to ensure the safety of ProTrans. Researchers are closely monitoring:
- Adverse events
- Hypoglycemia (low blood sugar) episodes
- Allergic reactions
- Changes in vital signs and laboratory tests
- Effects on the eyes (through ophthalmologic examination)
- Heart function (through ECG)
Future Prospects
If ProTrans proves to be safe and effective in these clinical trials, it could potentially revolutionize the treatment of Type 1 Diabetes. Some exciting possibilities include:
- Reducing or eliminating the need for daily insulin injections
- Improving long-term health outcomes for people with Type 1 Diabetes
- Offering a new approach to managing autoimmune diseases
However, it's important to note that ProTrans is still in the experimental stage. More research is needed to fully understand its benefits and potential risks before it can be widely available as a treatment option.